Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive Lymphomas
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of the protocol is to estimate the complete response rate of three
courses of the association of rituximab, navelbine, ifosfamide, mitoxantrone, and prednisone
in relapsed aggressive non hodgkin's B-cell lymphoma